Articles tagged with Hormone Therapy
A recent study found that COVID-19 can lead to lower testosterone levels in male patients, which may explain the better outcomes seen in female patients. The study also showed that hypogonadism, or low testosterone production, was present in over half of the male patients.
A new study confirms hormone therapy reduces biomarkers of inflammation in postmenopausal women, with greatest benefits seen in those nearing menopause. The study suggests hormone therapy may slow progression of atherosclerosis by targeting inflammatory processes.
Fetal estrogens, such as estetrol and estriol, show promising characteristics in reducing hot flashes and improving cardiovascular health. They may also provide added benefits that have yet to be fully explored, making them a promising new approach to hormone therapy.
Human intestinal organoids grown from stem cells help identify peptide YY as a possible therapeutic for severe malabsorption. The hormone allows 80% of mice to survive with just one injection per day, showing promise for treating congenital disorder.
In a 11-year study, testosterone therapy significantly reduced weight and improved various metabolic markers in obese men with low testosterone. The treatment also led to lower rates of mortality and cardiovascular events compared to controls.
The European Society of Endocrinology reviews evidence on hormone involvement in COVID-19 infection, disease severity, and treatment. Obesity, cardiovascular disease, and sex hormones are identified as risk factors.
A new breast cancer treatment developed by UIC researchers has shown safety and effectiveness in Phase 1 clinical trials, with no toxic side effects reported. The drug, TTC-352, halted disease progression in six patients with metastatic breast cancer, offering a promising alternative to traditional hormone therapy.
Researchers discovered increased levels of neuroprotein sortilin in pancreatic cancer cells, suggesting it as a potential therapeutic target. Sortilin's expression was found higher in female patients and contributed to invasive properties of pancreatic cancer cells.
A review article suggests postmenopausal women are at higher risk for developing nonalcoholic fatty liver disease (NAFLD) due to the decline in estrogen levels. Normal-weight women with normal lipid, glucose, and insulin levels are at low risk for NAFLD.
A new study by Brigham and Women's Hospital found that delaying radiation therapy for men with unfavorable intermediate-risk or high-risk localized prostate cancer, who are receiving radiation and hormone therapy, is unlikely to impact survival. This flexibility in radiation timing could help patients minimize exposure to COVID-19 by s...
A new study suggests that COVID-19 may cause deadly blood clots in pregnant women and those taking estrogen, highlighting the need for anticoagulation therapy or discontinuation of estrogen medicines. Research is underway to understand how the coronavirus causes blood clots, which could inform prevention strategies.
A new purification technique using molecular affinity interaction has been developed to purify therapeutic proteins with high efficiency and purity. The technique uses synthetic host molecules cucurbit[7]uril and adamantane to secure manufacturability, sterilization, and recyclability of purified materials.
A USC-led team found a fasting-mimicking diet combined with hormone therapy may increase the power of cancer hormone drugs and delay resistance in small clinical trials and mouse studies. Researchers observed reduced insulin, IGF1, and leptin levels, leading to potential anti-cancer activity.
Researchers from Osaka University found that adiponectin, a fat cell hormone, improves the efficacy of mesenchymal stem cell-based treatment for heart failure. The study showed that increasing adiponectin levels strengthens cardiac function following MSC therapy.
Researchers found that patients with sepsis had higher levels of GDF15 in their blood, which was correlated with mortality. In mice without the GDF15 gene, the absence of this hormone improved survival rates after bacterial infection.
Researchers found high-dose131I-metaiodobenzylguanidine treatment improved outcomes in refractory high-risk neuroblastoma patients. The study discovered a 42% event-free survival rate at 1 year and 16% at 5 years, with overall survival rates of 58% at 1 year and 42% at 5 years.
A systematic review of multiple sclerosis treatments found no effective interventions for cognitive symptoms, despite over half of affected individuals experiencing cognitive dysfunction. Researchers emphasize the need for future studies focusing on cognitive outcomes and standardized criteria to inform optimal treatment choices.
A recent study found that despite Oregon's strong laws protecting trans women from discrimination, they often struggle to navigate the healthcare system, leading to delayed or denied care. The study highlights the need for improved training and support for healthcare workers to address these challenges.
A phase 3 trial found that surgery and radiation after initial systemic therapy did not improve overall survival for women with stage IV breast cancer. The study suggests that these treatments should not be routine practice, instead focusing on proven therapies to prolong life.
Researchers with the ECOG-ACRIN Cancer Research Group presented new findings on breast cancer treatment trials, including TAILORx and NCI-MATCH. The studies found that women under 40 are at risk for early discontinuation of hormone therapy, and insurance status plays a key role in adherence to adjuvant hormone therapy.
Researchers at Stanford University have developed a way to combine insulin with amylin, a second hormone that plays a synergistic role in controlling blood sugar levels. The new technique involves a protective coating that allows the two hormones to coexist in a single shot, enabling patients to take a double-acting injection.
Researchers found that adding venetoclax to hormone therapy and CDK4/6 inhibitors can kill senescent cancer cells, potentially prolonging cancer response to therapy. The findings have underpinned a phase 1 clinical trial in Melbourne combining the treatments.
Researchers at Memorial Sloan Kettering Cancer Center discovered that nearly all cells in the prostate gland contribute to its regrowth after androgen-deprivation therapy. Luminal cells acquire stem-like properties without hormone influence, leading to implications for prostate cancer treatment and potential therapeutic strategies.
A new study found substantial variability in Medicare coverage and out-of-pocket costs for feminizing and masculinizing hormone therapies among older transgender individuals. The proportion of Medicare plans offering unrestricted coverage ranged from 5-100%, while out-of-pocket costs varied between $180-$2,176.
A new UCLA study has identified a key gene, reprimo, which regulates body temperature and may contribute to menopause-related weight gain. The research suggests that manipulating this gene could provide a safer alternative to hormone replacement therapy for alleviating symptoms.
The TAILORx trial found that women on hormone therapy also experienced cognitive decline, which leveled off over time. Cognitive function did not return to pre-treatment levels in either group, and hormone therapy may play a role in this impairment.
Interacting with therapy dogs for several minutes reduces self-reported anxiety and salivary cortisol levels among emergency providers. The study suggests a small benefit in stress reduction after the interaction, but the extent of the benefit is unclear.
A study of 158 transgender teens found that two-thirds have depression, with higher rates among males. Hormone therapy led to significant improvements in gender dysphoria for both affirmed males and females.
A large study has found that thyroid hormone replacement therapy in older adults is associated with a higher risk of death compared to no treatment. The study, published in the Journal of the Endocrine Society, suggests that age-specific TSH reference intervals can help determine the threshold for thyroid hormone treatment.
According to an analysis of patient forums, desiccated thyroid extract (DTE) is more effective than other thyroid hormone medications for improving symptoms and overall well-being. The treatment, also known as nature thyroid or Armour thyroid, has been used by 10%-25% of people with hypothyroidism.
A study led by James Cook University found that supervised exercise sessions can reduce the negative side effects of Androgen Deprivation Therapy (ADT) in prostate cancer patients. The research showed sustained benefits in cardiovascular risk profile and quality of life, but not in cardiopulmonary fitness and fatigue.
OCU400, a novel gene therapy product candidate, demonstrates efficacy in rescuing photoreceptors from degeneration by resetting retinal homeostasis. The treatment has the potential to be broadly effective across genetically diverse IRDs, offering hope for millions of people worldwide affected by inherited retinal degenerations.
Preliminary research suggests that taking estradiol within 6 years of menopause onset can prevent or slow atherosclerosis progression by reducing cholesterol deposits in artery walls. In contrast, starting therapy 10 years after menopause did not yield similar benefits.
Researchers found that adrenomedullin helps resolve lung damage and pulmonary hypertension caused by oxygen exposure in mice, suggesting a potential new therapy for bronchopulmonary dysplasia (BPD) and pulmonary hypertension. Adrenomedullin may also improve the quality of life of BPD-associated PH patients.
A new study reveals that habit, tradeoffs, and resource barriers are key factors influencing breast cancer therapy discontinuation. Black women were more likely to report challenges related to these barriers, highlighting the need for multi-barrier intervention strategies.
Researchers from the Technical University of Denmark have discovered a way to improve EPO production by knocking out specific genes in Chinese Hamster Ovary cells. This results in a 1.4-fold increase in production and significantly improved product quality, with up to 40% of the most active EPO form produced.
A blueprint for implementing transgender health programs in primary care is provided, including tips on accessing low-cost clinical training and generating organizational buy-in. The guide aims to address significant health inequities faced by this underserved population.
A new therapy option has been identified for early-stage breast cancer using the radiopharmaceutical 223RaCl2, which delays the growth of disseminated tumor cells. The treatment shows promise in delaying tumor progression and may be an adjuvant therapy option for select patients.
Researchers at the University of Texas Medical Branch have discovered that traumatic brain injuries can lead to a cascade of health issues, including fatigue, depression, and memory problems. Growth hormone replacement therapy has been shown to improve symptoms, but the mechanisms behind its effectiveness are still not fully understood.
Researchers discover that hormone resistant ER+ breast cancers have a 'rewired' 3D structure of DNA, altering gene activation and silencing. This change may explain how cancer cells evade hormone therapy, offering a potential path for reversal using existing drugs.
Researchers found that blocking androgen receptors can increase the density of prostate-specific membrane antigen (PSMA) sites on tumor surfaces, allowing for more targeted radiation therapy. This breakthrough could lead to more efficient treatment of advanced prostate cancer.
The American College of Physicians recommends testosterone treatment for men with age-related low testosterone only to treat sexual dysfunction. Testosterone treatment has shown small improvements in sexual and erectile function, but not in energy, vitality, or cognition.
The American College of Physicians recommends treating testosterone deficiency for only sexual dysfunction, discontinuing treatment if symptoms don't improve, and avoiding other reasons for treatment. Testosterone treatment should not be initiated to boost energy or cognitive function due to lack of evidence.
The NRG Oncology/NSABP B-42 trial found that extending letrozole therapy for five additional years improved disease-free survival in postmenopausal women with HR+ breast cancer. The study showed a 26% decrease in the risk of breast-cancer-free interval events and a 29% reduction in distant recurrence rates.
Hyperactive FOXA1 signaling triggers genome-wide reprogramming in endocrine-resistant breast cancer cells, leading to enhanced resistance to treatment and metastatic behaviors. An inhibitor of HIF-2a reduces migration and invasion of these cells, providing a potential therapeutic strategy.
A new study published in BJU International found that short-term exercise can reduce the adverse effects of hormone therapy on cardiovascular fitness and fatigue. Patients who underwent supervised aerobic and resistance training experienced improved cardiopulmonary fitness, reduced fatigue, and enhanced quality of life.
Researchers found luteolin suppresses both early stage prostate carcinogenesis and CRPC by inducing apoptosis. MicroRNA-8080 (miR-8080) recruited by luteolin down-regulates AR-V7, inhibiting tumorigenesis and enzalutamide resistance in CRPC.
Complementary therapies used to treat breast cancer skin lesions may delay wound healing and interfere with systemic treatments. Herbal products like green chiretta and feverfew have been shown to negatively impact blood clotting, exacerbating scarring and dressing effectiveness.
Researchers identify potential environmental risk factors and new treatment strategies for triple negative breast cancer (TNBC), an aggressive form of breast cancer. The study suggests that exposure to common chemicals may increase the risk of developing TNBC, and highlights the potential for combination therapy as a treatment option.
Researchers identify two molecules, PLXNA1 and PLXNA3, that help set up the sense of smell and pave the way to puberty. This finding may lead to a better understanding of Kallmann syndrome and its treatment.
Researchers found that women using hormonal contraception experienced reduced benefits from exposure therapy compared to those not taking oral contraceptives. Symptom severity decreased after therapy, but improved more for those without hormonal contraception.
A new analysis published in Annals of Oncology suggests that hormone therapy has a greater impact on women's quality of life compared to chemotherapy, especially in postmenopausal patients. This finding challenges current international guidelines recommending prolonged hormone therapy for 5-10 years.
USC researchers have successfully grown human testosterone-producing cells in the lab, paving the way to treat low testosterone with personalized replacement cells. The breakthrough could potentially bypass side effects associated with current treatments, such as infertility and increased risk of prostate cancer.
A recent analysis reveals that treatment of male breast cancer has evolved over the years, with certain patient- and tumor-related factors linked to better survival. The study found that older age, black race, multiple comorbidities, high tumor grade, and undergoing total mastectomy were associated with worse overall survival.
A new study published in the American Journal of Psychiatry found that gender-affirming surgery significantly reduces mental health treatment use among transgender individuals with gender incongruence. The study, which analyzed over 2,500 individuals, showed a 8% reduction in mental health treatment odds for every year since receiving ...
A new study published by The Menopause Society finds that fractional CO2 laser therapy is as effective and safe as vaginal estrogen in improving sexual and urinary functionality in postmenopausal women. After 6 months of follow-up, researchers reported similar improvements in symptoms such as vaginal dryness, itching, and burning.
A recent study has shown that targeting faulty DNA repair mechanisms can slow the progression of advanced prostate cancer and improve survival rates. The PROfound trial demonstrated a significant delay in cancer progression with olaparib, compared to new hormonal agents, in patients with metastatic, pre-treated prostate cancer.
A study by UCLA researchers found that adding ribociclib to standard hormone therapy significantly improves overall survival in postmenopausal women with advanced hormone-receptor positive/HER2- breast cancer. The combination treatment demonstrated a 28% reduction in risk of death and improved progression-free survival.
A new analysis finds that long-term hormone therapy increases mortality risk for men with low PSA levels after prostate surgery. The study suggests that patients with high PSAs should continue to receive hormone therapy in addition to radiation, but those with low PSAs may be better off without it.
A new study using WHI data found that hormone therapy decreases markers of insulin sensitivity and blood glucose in women, reducing the risk of Type 2 diabetes. The study focused on nine metabolites associated with diabetes development and found seven to be significantly decreased with hormone therapy.